A deep-dive for pharma/biotech IP strategists, pipeline analysts, and buy-side investors. Part I: The Japanese Pharmaceutical Market Sizing Up the […]
The pharmacy counter is one of the most consequential decision points in American healthcare. A prescription that a physician deemed
Generic Drugs Save America $445 Billion a Year. Here’s Why the Model Is Cracking. Read Post »
Who this is for: Pharma and biotech IP teams, portfolio managers, R&D leads, M&A counsel, and institutional investors with exposure
Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different
Drug Patent Prosecution: The Complete Strategic Playbook for Pharma IP Teams Read Post »
Who this is for: Pharma and biotech IP counsel, portfolio managers, R&D leads, generic drug strategy teams, business development executives,
Google Patents for Drug IP: The Free Tool That Creates Billion-Dollar Blind Spots Read Post »
A comprehensive framework covering due diligence, KPI architecture, IP asset valuation, technology roadmaps, and strategic governance across the full drug
When generic competition arrives, it arrives fast. Within the first 12 months of a major brand losing exclusivity, generic entrants
In-Licensing Branded Drugs: The Definitive IP Durability Playbook for Pharma Deal-Makers Read Post »
I. Executive Summary and Investment Thesis The Core Problem The generic drug industry saves the U.S. healthcare system roughly $216
Generic Drug Market: Why the Cheapest Medicine is Becoming the Most Expensive Problem Read Post »
Partnering with a Contract Development and Manufacturing Organization (CDMO) is no longer a simple procurement exercise. It is a fundamental
CDMO Selection: The Ultimate Checklist Read Post »
Get fresh news and insights, drug patent expirations & more…
